PDF Cover

Quizartinib Tablets Market

Quizartinib Tablets Market

The market for Quizartinib Tablets was estimated at $612.10 million in 2024; it is anticipated to increase to $1.04 billion by 2030, with projections indicating growth to around $1.63 billion by 2035.

Report ID:DS1802161
Author:Debadatta Patel - Senior Consultant
Published Date:April 2025
Datatree
Life Science
Pharmaceutical
Quizartinib Tablets
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Quizartinib Tablets Market Outlook

Revenue, 2024 (US$M)

$612M

Forecast, 2034 (US$B)

$1.49B

CAGR, 2024 - 2034

9.3%
The Quizartinib Tablets industry revenue is expected to be around $669.0 million in 2025 and expected to showcase growth with 9.3% CAGR between 2025 and 2034. The notable increase in market activity underscores the enduring importance of Quizartinib Tablets within the healthcare sector. Factors such as the growing occurrence of acute myeloid leukemia. An ailment for which Quizartinib is frequently prescribed. And substantial investments in pharmaceutical industries worldwide have further solidified the products significance. Additionally progress in studies and continual research endeavors to enhance the effectiveness of Quizartinib Tablets are also playing a role, in driving the products market traction forward.

Quizartinib Tablets are also referred to as AC220 tablets. Are taken orally to inhibit FLT inhibitors for the treatment of patients with acute myeloid leukemia who have an FLT2 ID mutation specifically. The effectiveness and lower likelihood of relapse when using this medication have contributed to its increasing popularity in times. Moreover improvements in accuracy increased knowledge about the illness and the option of using Quizartinib Tablets in conjunction with other therapies have all led to a surge, in worldwide demand.

quizartinib tablets market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Quizartinib Tablets market is projected to grow from $612.1 million in 2024 to $1.49 billion in 2034. This represents a CAGR of 9.3%, reflecting rising demand across Acute Myeloid Leukemia Treatment, Relapsed or Refractory AML Treatment and Clinical Trials for Other Malignancies.
  • Novartis International AG, Acerta Pharma, Apellis Pharmaceuticals Inc are among the leading players in this market, shaping its competitive landscape.
  • U.S. and Germany are the top markets within the Quizartinib Tablets market and are expected to observe the growth CAGR of 6.8% to 9.8% between 2024 and 2030.
  • Emerging markets including Brazil, India and Singapore are expected to observe highest growth with CAGR ranging between 8.9% to 11.6%.
  • Transition like Evolving Treatment Protocols is expected to add $125.7 million to the Quizartinib Tablets market growth by 2030
  • The Quizartinib Tablets market is set to add $877 million between 2024 and 2034, with manufacturer targeting Aggressive Systemic Mastocytosis & Other Oncological Conditions Therapeutic Use projected to gain a larger market share.
  • With Growing prevalence of acute myeloid leukemia, and Technological advancements in drug discovery, Quizartinib Tablets market to expand 143% between 2024 and 2034.
quizartinib tablets market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Quizartinib Tablets

The increasing prevalence of AML in developing countries results in a need for efficient treatment options. The utilization of Quizartinib tablets that demonstrate effectiveness, in challenging AML instances could address this demand by adapting product availability and pricing to match the changing market dynamics in these areas.

Growth Opportunities in North America and Asia Pacific

North America Outlook

The market for Quizartinib Tablets in North America is on a rise due to the growing number of cases of acute myeloid leukemia and significant investments in research and development driving this trend forward. High healthcare standards and a established regulatory framework contribute to the increasing use of these targeted therapy tablets which in turn pushes manufacturers to meet the rising demand. Competition is tough in this region with players such as Daiichi Sankyo and AstraZeneca strengthening their market approaches, for a larger share of the market. The Quizartinib Tablets market in North America is anticipated to experience growth due, to the rise of technology trends and personalized medicine approaches.

Asia Pacific Outlook

In the Asia Pacific region market for Quizartinib Tablets is projected to show growth in the near future due to an increase in AML patients caused by an aging population and changes in lifestyle which are driving factors for market expansion in this sector. Countries such as China, Japan and India have a stake in the market thanks to the improvement of healthcare facilities and government efforts towards healthcare progress. The competition scenario features a mix of international companies competing for a leading position, in the market. The increasing recognition among the public about AML and the advantages of Quizartinib tablets is expected to boost market expansion, in the Asia Pacific region.

Market Dynamics and Supply Chain

01

Driver: Growing Prevalence of Acute Myeloid Leukemia, and Increase in Healthcare Expenditure

The rising number of Acute Myeloid Leukemia cases globally is also a driver behind the market expansion of Quizartinib Tablets. Given that AMLs the predominant form of acute leukemia among adults there is also a growing need for impactful medications such as Quizartinib Tablets to address this pressing issue effectively. The drugs capacity to impede the proliferation of cells positions itself as a crucial element, in combating this persistent illness. Increased healthcare costs worldwide are also also a factor for the Quizartinib Tablets markets growth potential as countries allocate more resources to healthcare services and make advanced treatment options such as Quizartinib Tablets more accessible, to a wider population.
In times the progress in drug discovery tools has also resulted in the emergence of more effective and safer choices such as Quizartinib Tablets being introduced to the market scene. Thanks to technologies enabling thorough molecular and genetic investigations the development of targeted medications that exhibit precise actions is also made feasible.
02

Restraint: Regulatory Challenges

The strict rules and regulations that oversee the approval of medications in nations can pose considerable obstacles for Quizartinib Tablets in its journey to market availability and success. These regulations mandate testing and trials for drugs prior, to their release leading to a costly and time intensive procedure. As a result of these factors the achievement of market entry and profitability could be postponed, thereby restricting market expansion.
03

Opportunity: Technological Innovations Drive Demand and Market Expansion through Strategic Collaborations

The fast progress in the field of chemistry requires ongoing improvements in cancer treatment methods to keep up with the advancements in technology. Quizartinib Tablets are inhibitors of FLT3 ITD and AML that could greatly benefit from this technological advancement. These tablets provide a treatment approach in cases where traditional therapies may not only be effective enough. By integrating drug discovery methods with targeted Quizartinib therapy, new avenues, for revenue generation could be explored while addressing the unmet needs of patients.
Collaborating with companies and research institutions may accelerate the progress of developing and bringing Quizartinib tablets to market swiftly. This approach to growth could promote the exchange of knowledge and resources. Enable the joint development of enhanced treatment protocols for AML patients—helping to advance the position, in the market quickly.
04

Challenge: High Treatment Costs

The significant costs associated with the use of Quizartinib Tablets present a challenge in the healthcare sector for cancer treatment needs like acute myeloid leukemia patients due to the intensive research and development involved in their production process that demands higher pricing to offset expenses incurred therein Consequently this elevated treatment expense hinders accessibilities among patients, from varying socioeconomic backgrounds limiting the markets growth prospects extensively.

Supply Chain Landscape

1
Raw Material Procurement

Department of Pharmaceuticals

Active Pharmaceutical Ingredients

2
Drug Synthesis

Daiichi Sankyo

Deciphera Pharmaceuticals

3
Tablet Formulation

Baxter BioPharma Solutions

Recipharm

4
Distribution & Retail

Walgreens

CVS Health

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Quizartinib Tablets in Acute Myeloid Leukemia Treatment, Relapsed or Refractory AML Treatment & Clinical Trials for Other Malignancies

Acute Myeloid Leukemia Treatment

Quizartinib tablets are essential in treating acute myeloid leukemia . Belonginging in the category of protein kinase inhibitors Quizartinib specifically targets FLT gene mutations that play a role in AML development. By blocking the growth of cancer cells these tablets provide doctors with a weapon against this disease. Pharmaceutical companies such as Daiichi Sankyo have established a presence, in the AML treatment market with Quizartinib.

Relapsed or Refractory AML Treatment

Quizartinib tablets are commonly used for treating refractory acute myeloid leukemia cases with FTL 2 mutations because they are effective in targeting the FLT 2 gene and have been proven to enhance survival rates in patients with refractory AML condition. Major pharmaceutical companies such as Novartis and Pfizer have incorporated Quizartinib into their treatment plans, for AML patients well.

Clinical Trials for Other Malignancies

Quizartinib tablets are not only just limited to treating acute myeloid leukemia. Are also undergoing clinical trials for treating different forms of cancers as well in various research settings and pharmaceutical companies due to the wide ranging effectiveness of protein kinase inhibitors in combination treatments for battling differents of cancers thereby showcasing the potential of Quizartinib tablets beyond its initial use and the scope, for market growth opportunities.

Recent Developments

December 2024

Zenolabs shared news about the completion of phase III clinical trials, for their Quizartinib tablets. The results showed promise in treating acute myeloid leukemia .

October 2024

MedSource shared that there has been an increase in the worldwide supply of Quizartinib tablets due, to the growing occurrence of AML.

August 2024

Regentix started an investigation to assess how the use of Quizartinib tablets in combination, with other common AML medications could enhance the rate of patient response.

Quizartinib Tablets have emerged as a breakthrough in the healthcare sector with a specific focus on oncology—a noteworthy trend to discuss when talking about recent advancements in this field of medicine. These tablets have displayed effectiveness, in individuals facing acute myeloid leukemia conditions and have significantly impacted both the patients lives and the pharmaceutical market as a whole. The Quizartinib Tablets market is currently experiencing a period of change and growth.

Impact of Industry Transitions on the Quizartinib Tablets Market

As a core segment of the Pharmaceutical industry, the Quizartinib Tablets market develops in line with broader industry shifts. Over recent years, transitions such as Evolving Treatment Protocols and Streamlined Drug Manufacturing have redefined priorities across the Pharmaceutical sector, influencing how the Quizartinib Tablets market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Evolving Treatment Protocols

The pharmaceutical field has experienced a change with the arrival of Quizartinib Tablets designed mainly for the precise treatment of acute myeloid leukemia . The integration of these tablets into treatment plans has expanded the scope of therapy options to patients dealing with this condition effectively. Quizartinibs distinct method of operation involves targeting the FLT3 gene mutation commonly found in AML cases which enables a targeted strategy, in fighting the disease and subsequently enhancing patient survival rates and diagnostic outcomes. This industry transition is expected to add $125.7 million in the industry revenue between 2024 and 2030.
02

Streamlined Drug Manufacturing

The FDAs recognition of Quizartinib Tablets as an Orphan Drug has led to changes in the manufacturing sector by promoting specialization and efficiency in production methods. This designation highlights the drugs effectiveness in treating illnesses and motivates manufacturers to prioritize the production of these sought after specialized medications. As a result of this shift in focus by manufacturers there has been a surge in the availability of Quizartinib Tablets making treatment more accessible, for patients who were previously overlooked.

Related Reports

Loading related reports...